We serve Chemical Name:5-(chloromethyl)-1-methyl-3-thiophen-2-ylpyrazole CAS:876316-96-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-(chloromethyl)-1-methyl-3-thiophen-2-ylpyrazole
CAS.NO:876316-96-0
Synonyms:2-[5-(chloromethyl)-1-methylpyrazol-3-yl]thiophene;5-(Chloromethyl)-1-methyl-3-thien-2-yl-1H-pyrazole
Molecular Formula:C9H9ClN2S
Molecular Weight:212.69900
HS Code:2934999090
Physical and Chemical Properties:
Melting point:96ºC
Boiling point:336.3ºC at 760 mmHg
Density:1.33g/cm3
Index of Refraction:1.653
PSA:46.06000
Exact Mass:212.01700
LogP:2.88740
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-[5-(chloromethyl)-1-methylpyrazol-3-yl]thiophene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-(Chloromethyl)-1-methyl-3-thien-2-yl-1H-pyrazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-[5-(chloromethyl)-1-methylpyrazol-3-yl]thiophene Use and application,2-[5-(chloromethyl)-1-methylpyrazol-3-yl]thiophene technical grade,usp/ep/jp grade.
Related News: According to Plexxikon, GSK scientists were only able to make Tafinlar after talks with Plexxikon about a potential partnership; although those talks never turned into a licensing deal, GSK apparently channeled that information and created a rival drug. 10b-(benzo[d][1,3]dioxol-4-ylmethyl)-8,9-dimethoxy-6,10b-dihydro-3H-oxazolo[4,3-a]isoquinoline-1,3(5H)-dione manufacturers For its part, the FDA’s representative at the meeting, Doran Fink, M.D., said the drug regulator is “working as rapidly as possible to conduct a thorough and comprehensive” review of all the COVID-19 vaccines that have applied for full approval. Pfizer and Moderna recently submitted their applications for a full nod. 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6-methyl- suppliers Grégoire Boutonnet, Chief Operating Officer of NOVA, said: “I am thrilled to be joining the NOVA team at this exciting period of growth as we launch the Jinkō platform towards wider adoption in the clinical trial development space. N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]furan-2-carboxamide vendor & factory.
